Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.
作者： U-Ging Lo , Jer-Tsong Hsieh , Jer-Tsong Hsieh , Junhang Luo , Jiming Bao
DOI:
关键词:
摘要: Interferon is known as a pleiotropic factor in innate immunity, cancer immunity and therapy. Despite an objective short-term response of interferon (IFN) therapy renal cell carcinoma (RCC) patients, the potential adverse effect IFN on RCC cells not fully understood. In this study, we demonstrate that IFNs can enhance invasion via new mechanism IFIT5-mediated tumor suppressor microRNA (miRNA) degradation resulted elevation Slug ZEB1 epithelial-to-mesenchymal transition (EMT). Clinically, significant upregulation IFNγ signaling pathway (such IFNGR1, IFNGR2, STAT1 STAT2) observed patients with metastatic disease. Overall, study provides action IFN-elicited canonical regulating miRNAs. Most importantly, it highlights pro-metastatic IFNs, which could undermine clinical applicability for treating patients.
参考文章(74)
Santodonato L, Gabriele L, Kaido T, Belardelli F, Maury C, Woodrow D, Rozera C, Moss J, Proletti E, Ferrantini M, Local and Systemic Response of Mice to Interferon-α1 -Transfected Friend Leukemia Cells American Journal of Pathology. ,vol. 147, pp. 445- 460 ,(1995)
Jeffrey W. Pollard, Tumour-educated macrophages promote tumour progression and metastasis Nature Reviews Cancer. ,vol. 4, pp. 71- 78 ,(2004) , 10.1038/NRC1256
S. A. Rosenberg, J. J. Mule, R. L. Afreniere, J. C. Yang, Suyu Shu, Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. Journal of Immunology. ,vol. 139, pp. 285- 294 ,(1987)
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce, J. Michael White, Paul E. Swanson, Lloyd J. Old, Robert D. Schreiber, IFNγ, and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature. ,vol. 410, pp. 1107- 1111 ,(2001) , 10.1038/35074122
S. D. Fossa, Interferon in metastatic renal cell carcinoma. Seminars in Oncology. ,vol. 27, pp. 187- 193 ,(2000)
Masatoshi Eto, , Yoshiaki Kawano, Yoshihiko Hirao, Koji Mita, Yoichi Arai, Taiji Tsukamoto, Katsuyoshi Hashine, Akio Matsubara, Tomoaki Fujioka, Go Kimura, Nobuo Shinohara, Katsunori Tatsugami, Shiro Hinotsu, Seiji Naito, Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan BMC Cancer. ,vol. 15, pp. 667- 667 ,(2015) , 10.1186/S12885-015-1675-1
Sebastiano Buti, Melissa Bersanelli, Angelica Sikokis, Francesca Maines, Francesco Facchinetti, Emilio Bria, Andrea Ardizzoni, Giampaolo Tortora, Francesco Massari, Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anti-Cancer Drugs. ,vol. 24, pp. 535- 554 ,(2013) , 10.1097/CAD.0B013E3283609EC1
A Katagiri, R Watanabe, Y Tomita, E-cadherin expression in renal cell cancer and its significance in metastasis and survival. British Journal of Cancer. ,vol. 71, pp. 376- 379 ,(1995) , 10.1038/BJC.1995.76
Layne Dylla, Paul Jedlicka, Growth-promoting role of the miR-106a~363 cluster in Ewing sarcoma. PLOS ONE. ,vol. 8, ,(2013) , 10.1371/JOURNAL.PONE.0063032
Ion Gresser, The antitumor effects of interferon: a personal history. Biochimie. ,vol. 89, pp. 723- 728 ,(2007) , 10.1016/J.BIOCHI.2007.03.005